2. Signaling Pathways
  3. Apoptosis
  4. Ferroptosis

Ferroptosis

Ferroptosis

Ferroptosis

Related Products

PDF 0.68 MB

Ferroptosis is a non-apoptotic form of regulated cell death. It is distinct from other regulated cell death phenotypes, such as apoptosis and necroptosis. Ferroptosis is characterized by extensive lipid peroxidation, which can be suppressed by iron chelators or lipophilic antioxidants. Mechanistically, Ferroptosis inducers are divided into two classes: (1) inhibitors of cystine import via system xc− (e.g., Erastin), which subsequently causes depletion of glutathione (GSH), and (2) covalent inhibitors (e.g., (1S, 3R)-RSL3) of glutathione peroxidase 4 (GPX4). Since GPX4 reduces lipid hydroperoxides using GSH as a co-substrate, both compound classes ultimately result in loss of GPX4 activity, followed by elevated levels of lipid reactive oxygen species (ROS) and consequent cell death.

Ferroptosis is an iron- and ROS-dependent form of regulated cell death (RCD). Misregulated Ferroptosis has been implicated in multiple physiological and pathological processes, including cancer cell death, neurotoxicity, neurodegenerative diseases, acute renal failure, drug-induced hepatotoxicity, hepatic and heart ischemia/reperfusion injury, and T-cell immunity.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-186144
    WMK-2
    		Inducer
    WMK-2 is a 1,2,4,5-tetraoxane derivative and ferroptosis inducer with broad-spectrum anticancer activity. WMK-2 generates hydroxyl radicals and lipid ROS to induce ferroptosis in cancer cells and cancer stem cells. WMK-2 can be used for the research of cancer.
    WMK-2
  • HY-183791A
    Ferroptosis/apoptosis inducer-5
    		Inducer
    Ferroptosis/apoptosis inducer-5 is an orally active inducer of Ferroptosis and Apoptosis. Ferroptosis/apoptosis inducer-5 downregulates GPX4, upregulates ACSL4, promotes ROS production, activates the Caspase cascade, induces Mitochondrial dysfunction, and alters the Bcl-2/Bax balance. Ferroptosis/apoptosis inducer-5 significantly inhibits tumor growth in a pancreatic cancer xenograft mouse model. Ferroptosis/apoptosis inducer-5 can be used for the research of pancreatic cancer.
    Ferroptosis/apoptosis inducer-5
  • HY-170509
    Ferroptosis-IN-17
    		Inhibitor
    Ferroptosis-IN-17 (Compound 18) is a ferroptosis (Ferroptosis) inhibitor with an EC50 value of 0.57 μM. Ferroptosis-IN-17 reduces intracellular ferrous ion accumulation, lipid peroxidation, and effectively restores the levels of glutathione (GSH) and glutathione peroxidase 4 (GPX4). Ferroptosis-IN-17 shows good solubility and significant metabolic stability in rat plasma. Ferroptosis-IN-17 is promising for research in tumor suppression, neurodegenerative diseases, and cardiovascular diseases.
    Ferroptosis-IN-17
  • HY-W018161S
    Hexadecanedioic acid-d28
    		99.21%
    Hexadecanedioic acid-d28 is the deuterium labeled Hexadecanedioic acid (HY-W018161). Hexadecanedioic acid (Thapsic acid) is an orally active metabolite produced by B. uniformis. Hexadecanedioic acid inhibits IRE1α-XBP1s-mediated flipogenesis and ferroptosis. Hexadecanedioic acid downregulates XBP1 and Hrd1 expression, activates the Nrf2/SLC7A11/GPX4 pathway. Hexadecanedioic acid can be used for the research of metabolic-associated fatty liver disease.
    Hexadecanedioic acid-d<sub>28</sub>
  • HY-175000
    L14-8
    		Inducer
    L14-8 is a potent ferroptosis inducer. L14-8 promotes PLK1 degradation via ubiquitination, increasing TP53 phosphorylation to enhance SAT1 transcription, thereby triggering ferroptosis and cancer cell death. L14-8 can be used for the study of advanced prostate cancer.
    L14-8
  • HY-162311
    Anticancer agent 194
    		Inhibitor
    Anticancer agent 194 (compound 10p) is a ferroptosis and autophagy inducer. Anticancer agent 194 arrests colon cancer cell cycle at G2/M phase, but can't induce cell apoptosis. Anticancer agent 194 independently triggeres cell ferroptosis and autophagy through the massive accumulation of ROS.
    Anticancer agent 194
  • HY-P10852
    TAT-MKK3b
    		Inhibitor
    TAT-MKK3b is a p38 peptide inhibitor. TAT-MKK3b can inhibit p38 phosphorylation. TAT-MKK3b has renal targeting, ROS-scavenging, and ferroptosis-mitigating capabilities. TAT-MKK3b improves acute kidney injury and its progression to chronic kidney disease.
    TAT-MKK3b
  • HY-N0504S2
    Lovastatin-d3
    		Activator
    Lovastatin-d3 is deuterium labeled Lovastatin. Lovastatin is a cell-permeable HMG-CoA reductase inhibitor used to lower cholesterol.
    Lovastatin-d<sub>3</sub>
  • HY-169287
    TriPEX-ClO4
    		Inhibitor
    TriPEX-ClO4 is a cationic fluorescent anticancer agent capable of BBB penetration. TriPEX-ClO4 can induces apoptosis and ferroptosis and can be used for study of cancer and brain diseases.
    TriPEX-ClO4
  • HY-P992180
    AMB8LK
    AMB8LK is a human monoclonal antibody targeting H-ferritin, with specificity for tumor-associated heterologous ferritin. AMB8LK specifically recognizes and binds to H-ferritin overexpressed on the surface of tumor cells. AMB8LK can be used in research related to cancer and immune diseases.
    AMB8LK
  • HY-175852
    Ferroptosis inducer-11
    		Inducer
    Ferroptosis inducer-11 is a ferroptosis inducer. Ferroptosis inducer-11 exhibits potent cytotoxicity against HCT-116, NCM-60 and HT-29 cells with IC50 values of 0.43 μM, 3.14 μM and 0.48 μM, respectively. Ferroptosis inducer-11 strongly suppresses GPX4 enzymatic activity with an IC50 of 1.86 μM. Ferroptosis inducer-11 induces ferroptosis, as well as increases intracellular lipid ROS, malondialdehyde (MDA), and Fe2+ levels, while decreasing glutathione (GSH) levels in colon cancer cells. Ferroptosis inducer-11 can be used for the study of colon cancer.
    Ferroptosis inducer-11
  • HY-N0193S1
    Artesunate-d4
    		Activator 99.9%
    Artesunate-d4 is deuterium labeled Artesunate. Artesunate is an inhibitor of both STAT-3 and exported protein 1 (EXP1).
    Artesunate-d<sub>4</sub>
  • HY-168261
    CQ-ER
    		Inducer
    CQ-ER is a Coumarin (HY-N0709)-Quinazolinone based endoplasmic reticulum (ER)-targeted photosensitizer. CQ-ER can cause ferroptosis, thereby enhancing photodynamic therapy (PDT).
    CQ-ER
  • HY-N17850
    5-Hydroxy-6,7-dimethoxyflavone
    		Inhibitor
    5-Hydroxy-6,7-dimethoxyflavone is an orally active inhibitor of ferroptosis (Ferroptosis). 5-Hydroxy-6,7-dimethoxyflavone inhibits H1N1 virus-induced ferroptosis by upregulating the expression of SLC7A11 and GPX4. 5-Hydroxy-6,7-dimethoxyflavone alleviates inflammatory responses and inhibits apoptosis by suppressing the activation of the NF-κB and p38 MAPK signaling pathways. 5-Hydroxy-6,7-dimethoxyflavone can be used in studies related to H1N1 influenza virus infection.
    5-Hydroxy-6,7-dimethoxyflavone
  • HY-161668
    Ru-Poma
    		Inducer
    Ru-Poma is a Ru(II)-based photosensitizer, which attenuates Cisplatin (HY-17394)-resistant tumor through photodynamic therapy (PDT). Ru-Poma photodegrades CRBN through a Pomalidomide (HY-10984) moiety. Ru-Poma induces ferroptosis, through an increase in lipid peroxide, downregulation of GPX4 and GAPDH expression. Ru-Poma exhibits cytotoxicity in A549, with IC50 of 18.46 μM and 0.37 μM in dark and upon irradiation, respectively.
    Ru-Poma
  • HY-17359S
    Deferasirox-d4
    		Inhibitor
    Deferasirox-d4 is the deuterium labeled Deferasirox. Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload.
    Deferasirox-d<sub>4</sub>
  • HY-14291S2
    Vildagliptin-13C5,15N
    		Inhibitor
    Vildagliptin-13C5,15N (LAF237-13C5,15N; NVP-LAF 237-13C5,15N) is a 13C- and 15N-labeled Vildagliptin (HY-14291). Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity.
    Vildagliptin-<sup>13</sup>C<sub>5</sub>,<sup>15</sup>N
  • HY-50898S1
    Lapatinib-d7 dihydrochloride
    		Activator
    Lapatinib-d7 dihydrochloride is the deuterium labeled Lapatinib dihydrochloride. Lapatinib (GW572016) dihydrochloride is a potent, orally active inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively.
    Lapatinib-d<sub>7</sub> dihydrochloride
  • HY-W738533
    Pioglitazone-d4 hydrochloride
    Pioglitazone-d4 hydrochloride (U 72107A-d4; AD 4833-d4) is the deuterium labeled Pioglitazone hydrochloride (HY-14601). Pioglitazone hydrochloride is a potent and selective PPARγ agonist with EC50s of 0.93 and 0.99 μM for human and mouse PPARγ, respectively.
    Pioglitazone-d<sub>4</sub> hydrochloride
  • HY-175633
    ML210-ansaFc
    		Inducer
    ML210-ansaFc (Compound III-13) is a covalent GPX4 inhibitor with a -ferrocenophane group (IC50 of 3.4 μM). ML210-ansaFc potently induces ferroptosis by increasing the level of ROSand promoting lipid peroxidation (LPO) in cancers cells. ML210-ansaFc has an anticancer activity and suppresses tumor growth in tumor 3D spheroids. ML210-ansaFc can be used for cancer therapy resistance research.
    ML210-ansaFc
Cat. No. Product Name / Synonyms Application Reactivity
All Rights Reserved.
Download Ferroptosis Signaling Pathway Map.